You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新股暗盤 | 中國抗體-B(3681.HK)暗盤段跌4.6%
格隆匯 11-11 17:06
格隆匯11月11日丨據輝立證券,中國抗體-B(3681.HK)暗盤段報7.25港元,較發行價7.6港元跌4.6%。公司是專門研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司,主要研製以單克隆抗體為基礎的生物藥。截至2017年及2018年12月31日止年度以及截至2019年4月30日止四個月,公司的年/期內虧損分別為5190萬元、8360萬元及2840萬元人民幣。公司此次全球發售約1.82億股,其中香港發售1821.3萬股,國際發售約1.64億股,每手300股,淨籌12.86億港元;香港公開發售獲12.87倍認購,國際發售獲超額認購約1.38倍。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account